Autoimmune hepatitis with giant-cell transformation.
ABSTRACT Giant-cell hepatitis (GCH), also known as postinfantile or syncytial giant cell hepatitis, is a frequent pattern of liver injury in the neonate, primarily seen in the first three months of life. Few cases in adults have been reported, some of them associated to autoimmune diseases such as autoimmune hepatitis.
We present a case of autoimmune hepatitis with giant cell transformation in a 39 year old male with polyarthritis. We discuss his clinical presentation and course. We made a review of the literature of agents associated to this diagnosis, the mechanisms involved in the formation of giant hepatocytes, the histological findings, clinical course, treatment options and prognosis of this rare entity.
In conclusion, the clinical course varies from normalization of hepatic histology to progression to cirrhosis and liver failure. The prognosis is dictated by the underlying liver disease and in the setting of autoimmune hepatitis the clinical course is usually severe with most of the patients progressing to cirrhosis. Prolonged treatment with corticosteroids and immunosuppressants is usually effective in rendering the cirrhosis inactive.
- [Show abstract] [Hide abstract]
ABSTRACT: Giant cell hepatitis is a well-known histological feature of several neonatal and infantile liver diseases. In contrast, postinfantile giant cell hepatitis is rarely identified in adult liver biopsies. It has been associated with varying etiologies, mainly viral infections, drug toxicity, and autoimmunity. Here, we report an 18-year-old, previously healthy man with acute liver failure, who showed giant cell hepatitis in a liver biopsy. There was no evidence of viral hepatitis A-E, autoimmunity, and no drug history. Diagnostic work-up revealed Wilson's disease as the underlying disease. As syncytial giant cell formation is thought to be a uniform reaction pattern not related to any specific etiology, copper toxicity in Wilson's disease might cause giant cell formation. In contrast, our patient recalled a recent cytomegalovirus infection, which was confirmed serologically. Therefore, the giant cell formation might also be a fingerprint of an intercurrent cytomegalovirus infection as the common trigger for both giant cell hepatitis and decompensation of Wilson's disease.European journal of gastroenterology & hepatology 03/2012; 24(3):328-31. · 1.66 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: The aim of this study is to determine whether amitotic division or nuclear proliferation is involved in the formation of giant cells (GCs) in giant cell hepatitis (GCH). Liver sections from 18 pediatric patients with idiopathic infantile GCH and 12 patients with postinfantile GCH were evaluated for the expression of proliferating cell nuclear antigen (PCNA) and human histone 3 (H3) mRNA, transforming growth factor-alpha (TGF-α), TGF-β1, hepatocyte growth factor (HGF), and epidermal growth factor receptor (EGFR). Proliferation markers were detected in 1% to 80% in the nuclei of GC and non-GC hepatocytes in 10 of 18 (56%) infantile GCH biopsies and 11 of 12 (92%) postinfantile GCH biopsies, but not in normal liver. The expression of proliferation markers in GCs paralleled that in non-GC hepatocytes (P < 0.05 for both markers). TGF-α and EGFR were detected in both GCs (9/29 and 4/30 patients with infantile or postinfantile GCH, respectively) and non-GC hepatocytes (15/29 and 11/30 patients with infantile or postinfantile GCH, respectively). TGF-β1 and HGF were detected mainly in sinusoidal cells in 20 of 29 and 10 of 30 patients with infantile or postinfantile GCH, respectively; the expression of HGF was positively correlated with PCNA and H3 mRNA in non-GC hepatocytes and with H3 mRNA in GCs (P < 0.01). Hepatic expressions of nuclear proliferation markers and growth factors were similar in infantile and postinfantile GCH, nuclear proliferation markers were detected in both GCs and non-GC hepatocytes in a high proportion of patients, and expression of HGF correlated positively with the proliferation markers. These data indicate that nuclear proliferation may contribute to the pathogenesis of GCs in at least a proportion of patients with GCH. A model for the pathogenesis of GCH is proposed.Journal of pediatric gastroenterology and nutrition 01/2011; 52(1):65-72. · 2.18 Impact Factor
- Journal of Fish Diseases 06/2013; · 1.51 Impact Factor
Annals of Hepatology 8(1) 2009: 68-70
Annals of Hepatology 2009; 8(1): January-March: 68-70
Autoimmune hepatitis with giant-cell transformation
José Estradas;1 Virginia Pascual-Ramos;2 Braulio Martínez;3 Misael Uribe;1 Aldo Torre1
1Department of Gastroenterology.
2Department of Rheumatology and Immunology.
3Department of Pathology.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador
Address for correspondence:
Aldo Torre, MD. M.Sc.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador
Vasco de Quiroga 15, Section XVI, Tlalpan, Mexico City
Telephone: +55 5573 3418
Fax: +55 5655 0942
Manuscript received and accepted:
10 September and 27 November, 2008
Background/Aims: Giant-cell hepatitis (GCH), also
known as postinfantile or syncytial giant cell hepatitis,
is a frequent pattern of liver injury in the neonate, pri-
marily seen in the first three months of life. Few cases
in adults have been reported, some of them associated
to autoimmune diseases such as autoimmune hepatitis.
Methods: We present a case of autoimmune hepatitis
with giant cell transformation in a 39 year old male
with polyarthritis. We discuss his clinical presentation
and course. We made a review of the literature of
agents associated to this diagnosis, the mechanisms in-
volved in the formation of giant hepatocytes, the histo-
logical findings, clinical course, treatment options and
prognosis of this rare entity. Results and conclusions:
In conclusion, the clinical course varies from normal-
ization of hepatic histology to progression to cirrhosis
and liver failure. The prognosis is dictated by the un-
derlying liver disease and in the setting of autoimmune
hepatitis the clinical course is usually severe with most
of the patients progressing to cirrhosis. Prolonged
treatment with corticosteroids and immunosuppres-
sants is usually effective in rendering the cirrhosis in-
Key words: Autoimmune hepatitis, giant-cell hepatitis,
postinfantile giant cell hepatitis, syncytial giant cell
Giant-cell hepatitis (GCH), also known as postinfan-
tile or syncytial giant cell hepatitis, is a frequent pattern
of liver injury in the neonate, primarily seen in the first
three months of life. Few cases in adults have been re-
ported, some of them associated to autoimmune diseases
such as autoimmune hepatitis.
We herein present a case of autoimmune hepatitis with
giant cell transformation in a 39 year old male with pol-
yarthritis involving the shoulders, elbows, wrists, metac-
arpophalangeal and proximal interphalangeal joints,
knees, ankles and metatarsophalangeal joints. He had a 5
month history of asthenia, weight loss (20 kg), dry cough
and morning stiffness. He admitted taking non-steroidal
anti-inflammatory drugs (NSAIDs) for pain relief.
On physical examination the patient was found
cachectic with arthritis of the mentioned joints. Neither
hepatomegaly nor tenderness on the right upper quad-
rant was found on palpation.
Laboratory studies showed WBC 18.8 K/μL, hemo-
globin 12.1 g/dL, platelets 611 K/μL, ALT 74 U/L, AST
59 U/L, GGT 158 U/L, bilirubins were within normal lim-
its, alkaline phosphatase was of 226 U/L, albumin 2.76
g/dL, and globulines of 3.94.
The rheumatoid factor (nephelometry) was slightly
positive: 40.51 UI/mL, anti-cyclic citrullinated peptide
autoantibody (2nd generation ELISA) and antinuclear
antibodies (immunofluorescence) were both negative,
anti-neutrophil cytoplasmic autoantibodies (ANCAs)
(immunofluorescence) showed a c-ANCA pattern in a ti-
tle of 1:320 with negative myeloperoxidase and pro-
teinase-3 (ELISA). Serum levels of complement were de-
creased (C3 59.5 mg/dL, C4 9.0 mg/dL), the viral pro-
file was negative.
The chest X ray showed an apparent widening of the
mediastinum, a chest CT was performed and showed a
nodular lesion with central necrosis in the anterior me-
diastinum and mediastinal adenomegalies. The medi-
astinal mass was found to be an atypical thymoma
type B3 (World Health Organization Classification) af-
ter the surgical excision and pathological examina-
tion were performed, radiotherapy was indicated after-
He was started on chloroquine, sulfasalazine and pred-
nisone which relieved the rheumatologic symptoms, but
after 6 months of treatment he became jaundiced and had
J Estradas et al. Autoimmune hepatitis and giant-cell hepatitis
a progressive increment of bilirrubins (total bilirubins
11.2 mg/dL, direct bilirubins 6.4 mg/dL) and transami-
nases (ALT: 523 U/L, AST: 187 U/L) Serum globulines
were within normal range and anti-mitochondrial anti-
bodies were negative. Drug toxicity, biliary tract disease
and infectious causes were excluded.
A liver biopsy was performed and showed interface
hepatitis with mild portal and periportal lymphoplasma-
cytic inflammation, hepatocyte swelling and necrosis
(Figure 1). Giant multinucleated hepatocytes were
present in more than 50% of the biopsy, predominantly
in periportal area (Figure 2); other histological findings
were mild lobular inflammation, necrosis and mild inter-
laminar fibrosis. The diagnosis of autoimmune hepatitis
with giant cell transformation was concluded.
The final «Autoimmune Hepatitis Score» for the diag-
nosis of autoimmune hepatitis was: 20.1
He was started on prednisone 40 mg and azathioprine
100 mg daily, he has been attending our clinic for regu-
lar check-ups and his clinical and biochemical profile
have markedly improved after one year of treatment.
Giant cell hepatitis (GCH) is an infrequent presenta-
tion of liver injury in the adulthood. It is more common-
ly described in neonates as a response of immature hepa-
tocytes to a variety of insults such as cholestasis,2-4 and
when it occurs in adults, it is known as postinfantile giant
Agents that have been associated to this diagnosis in-
clude: infections such as hepatitis A, B and C viruses,6
HIV, EBV, and paramyxovirus;7 drugs as methotrexate, 6-
mercaptopurine, p-aminosalicylic acid, chlorpromazine,
vinyl chloride, clomethacin,2 and a case of GCH after a
human herpesvirus 6-induced adverse drug reaction has
also been described;8 diseases like sickle cell anemia, au-
toimmune hemolytic anemia, chronic lymphocytic leu-
kaemia,9 non-Hodgkin’s lymphoma involving the liver,4
polyarteritis nodosa,10 autoimmune hepatitis (type I and
II5,11), ulcerative colitis (suggesting that GCH may be in-
cluded in the list of hepatic complications of inflamma-
tory bowel disease),2,12 primary biliary cirrhosis13 and pri-
mary sclerosing cholangitis;3 congenital metabolic dis-
eases such as alpha 1-antitrypsin deficiency or
haemosiderosis, and in some other cases the etiology re-
Giant-cell transformation is a nonspecific reaction to
various stimuli rather than a specific disease process.4,14
There are two possible mechanisms in the formation of
giant hepatocytes: the fusion of individual cells to form
a syncytium (therefore the used term «syncytial giant cell
hepatitis»15) and the failure of the cytoplasm to divide at
the time of nuclear division.4,5,14
The diagnosis is made when multinucleated syncytial
hepatocytes are observed in liver biopsy,3 they may be
seen as isolated clusters of giant cells or multinucleated
giant cells over mononuclear hepatocytes, appearing pre-
dominantly in zone 3 or 1 of the Rappaport acinus. Other
histological findings include portal inflammation (more
commonly lymphocytic, but plasma cells and neutro-
phils can also be seen), varying degrees of acinar inflam-
mation, hepatocellular necrosis, ballooning degenera-
tion, bile duct lesions (nonsuppurative destructive cho-
langitis, periductal scarring, and ductopenia), periportal
fibrosis and cirrhosis.4
The clinical course may vary from normalization of
hepatic histology, either spontaneously or by medical
treatment, to progression to cirrhosis and liver failure.2,3
The prognosis is dictated by the underlying liver dis-
ease2,16 and in the setting of autoimmune hepatitis the
clinical course is usually severe with most of the patients
progressing to cirrhosis. Prolonged treatment with corti-
costeroids and immunosuppressants is usually effective
Figure 1. Microscopic view of the liver biopsy showing interface
hepatitis with mild portal and periportal lymphoplasmacytic infla-
mmation, hepatocytes swelling and necrosis.
Figure 2. Giant multinucleated hepatocytes in more than 50% of
the biopsy, predominantly in periportal area.
Annals of Hepatology 8(1) 2009: 68-7070
ESTE DOCUMENTO ES ELABORADO POR MEDI-
in rendering the cirrhosis inactive.5 A reduction in the
number of giant hepatocytes after treatment of the au-
toimmune and cholestatic features has been reported pre-
viously, which may suggest that an autoimmune mecha-
nism as well as cholestasis may be involved in the patho-
genesis of giant cell transformation.2,3,5,17,18
Most of the patients with GCH have an unfavorable
prognosis, with a rapidly progressive course leading to
death or the need for orthotopic liver transplantation, al-
though GCH can recur in liver allograft.19,20
1.Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK,
Cancado EL, et al. International Autoimmune Hepatitis Group
Report: review of criteria for diagnosis of autoimmune hepatitis.
J Hepatol 1999; 31: 929-38.
Labowitz J, Finklestein S, Rabinovitz M. Postinfantile giant cell
hepatitis complicating ulcerative colitis: a case report and review
of the literature. Am J Gastroenterol 2001; 96: 1274-7.
Protzer U, Dienes HP, Bianchi L, Lohse AW, Helmreich-Becker
I, Gerken G, Meyer zum Buschenfelde KH. Post-infantile giant
cell hepatitis in patients with primary sclerosing cholangitis and
autoimmune hepatitis. Liver 1996; 16: 274-82.
Devaney K, Goodman ZD, Ishak KG. Postinfantile giant-cell
transformation in hepatitis. Hepatology 1992; 16: 327-33.
Ben-Ari Z, Broida E, Monseliese Y, Kazatsker A, Baruch J, Pappo
O, et al. Syncytial giant-cell hepatitis due to autoimmune hepati-
tis type II (LKM1+) presenting as subfulminant hepatitis. Am J
Gastroenterol 2000; 95: 799-801.
Kryczka W, Walewska-Zielecka B, Dutkiewicz E. Acute serone-
gative hepatitis C manifesting itself as adult giant cell hepatitis –
a case report and review of literature. Med Sci Monit 2003; 9
Suppl 3: 29-31.
Philips MJ, Blendis LM, Poucell S, offterson J, Petric M, Roberts
E, et al. Syncitial giant-cell hepatitis. Sporadic hepatitis with dis-
tinctive pathological features, a severe clinical course, and
paramyxomal features. N Eng J Med 1991; 324: 455-60.
Kuntzen T, Friedrichs N, Fischer HP, Eis-Hübinger AM,
Sauerbruch T, Spengler U. Postinfantile giant cell hepatitis with
autoimmune features following a human herpesvirus 6-induced
adverse reaction. Eur J Gastroenterol Hepatol 2005; 17: 1131-4.
Alexopoulou A, Deutsch M, Ageletopoulou J, Delladetsima JK,
Marinos E, Kapranos N, et al. A fatal case of postinfantile giant
cell hepatitis with chronic lymphocytic leukaemia. Eur J
Gastroenterol Hepatol 2003; 15: 551-5.
10. Koskinas J, Deutsch M, Papaioannou C, Kafiri G, Hadzivannis S.
Post-infantile giant cell hepatitis associated with autoimmune
hepatitis and polyarteritis nodosa. Sand J Gastroenterol 2002;
11. Scheuer PJ, Lefkowitch JH. Chronic hepatitis. In: WB Saunders,
eds. Liver Biopsy Interpretation. 6th ed. London, 2000: 164-
12. Anagnostopoulos GK, Margantinis G, Tsiakos S, Kostopoulos P,
Grigoriadis K, Arvantidis D. Postinfantile giant-cell hepatitis as-
sociated with ulcerative colitis and autoimmune hepatitis. J
Gastroenterol Hepatol 2006; 21: 1863-4.
13. Watanabe N, Takashimizu S, Shiraishi K, Kagawa T, Nishizaki
Y, Mine T, et al. Primary biliary cirrhosis with multinucleated
hepatocelular giant cells: implications for pathogenesis of pri-
mary biliary cirrhosis. Eur J Gastroenterol Hepatol 2006; 18:
14. Lau JY, Koukoulis G, Mieli-Vergani G, Portmann BC, Williams
R. Syncytial giant-cell hepatitis - a specific disease entity? J Hepatol
1992; 15: 216-19.
15. Thaler H. Post-infantile giant cell hepatitis. Liver 1982; 2: 393-
16. Tordjmann T, Grimbert S, Genestie C, Freymuth F, Guettier C,
Callard P, et al. [Adult multi-nuclear hepatitis. A study in 17
patients]. Gastroenterol Clin Biol 1998; 22: 305-10.
17. Pittau S, Morelli S, Venturini E, Boldorini R, Sartoi M. [Post-
infantile giant cell hepatitis. Clinical and histological response
to immunosuppressive therapy]. Recenti Prog Med 1998; 89:
18. Eroglu Y, Düzovali O, Kavucku S, Irken G, Büyükgebiz B.
Combination of steroid with azathioprine in treatment of giant
cell autoimmune hepatitis. Turk J Pediatr 1997; 39: 565-71.
19. Pappo O, Yunis E, Jordan JA, Jaffe R, Mateo R, Fung J, et al.
Recurrent and de novo giant cell hepatitis after orthotopic liver
transplantation. Am Surg Pathol 1994; 18: 804-13.
20. Shah JA, Steinbrecher UP, Erb SR, Tha SP, Yoshida EM. Recur-
rent giant cell hepatitis in an 18 year old liver transplant patient.
Ann Hepatol 2008; 7: 257.